Finanzen von BioLife Solutions, Inc. (BLFS)BLFSBioLife Solutions, Inc.

BioLife Solutions, Inc. (BLFS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product Revenue-Cell processing, accounting for 90.1% of total sales, equivalent to $25.28M. Other significant revenue streams include Rental Revenue- Evo and thaw and Product Revenue- Evo and thaw. Understanding this composition is critical for investors evaluating how BLFS navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, BioLife Solutions, Inc. maintains a gross margin of 63.69%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.96%, while the net margin is 158.45%. These profitability ratios, combined with a Return on Equity (ROE) of 12.83%, provide a clear picture of how effectively BLFS converts its operational activities into shareholder value.

In the context of the broader market, BLFS competes directly with industry leaders such as INSP and BWAY. With a market capitalization of $1.72B, it holds a leading position in the sector. When comparing efficiency, BLFS's gross margin of 63.69% stands against INSP's 85.48% and BWAY's 75.17%. Such benchmarking helps identify whether BioLife Solutions, Inc. is trading at a premium or discount relative to its financial performance.

BioLife Solutions has shown significant revenue growth, with Q2 2026 revenue at $28,466,000, and a net income of $45,104,000, reflecting a strong recovery. The gross margin is stable at around 63.69%.